GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV ...

Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.

The federal government defines Schedule I drugs as having a strong potential for abuse and no currently accepted medical use, ...

The drugs are designed to be started at lower doses that gradually ... “The demand for tirzepatide is very strong,” Lilly ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of ...

Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.

Biogen on Wednesday reported a first-quarter profit that exceeded estimates as the Cambridge drug maker cut costs and sales ...

Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer ...

GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding ...

Thanks to growing sales of AbbVie’s newer immunology drugs, the company is raising its full-year earnings projections. In the ...

Moreover, the company’s lead drug candidate, dordaviprone, has shown promise with its Fast Track Designation from the FDA and Rare Pediatric Disease Designation, highlighting its potential to meet ...

Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ...